Antineoplastics
1
Reactions 1345 - 2 Apr 2011 ★ Antineoplastics Dermatitis, dysgeusia (first report for carboplatin) and stomatitis (first report for trastuzumab) in patients with vitamin D deficiency: 2 case reports Two women developed various toxicities, including dysgeusia, following cancer chemotherapy. In January 2010, a 59-year-old woman started receiving docetaxel 75 mg/m 2 , carboplatin at AUC 6 and trastuzumab 6 mg/kg on day 1 of each cycle [routes not stated]. She developed moderate dermatitis, moderate stomatitis and significant dysgeusia 1 week after receiving the second cycle. Two weeks after the third cycle, she presented with a painful fissure on the flexor side of her right thumb, which was surrounded by flaky skin. A 25 hydroxyvitamin D (25-OHD) level of 6.3 ng/mL confirmed vitamin D deficiency. She received colecalciferol [vitamin D3] daily. At a follow-up 6 days later, her thumb lesion had markedly improved and the fourth chemotherapy cycle was administered at the same dosage the next day. The lesions had almost totally resolved about 2 weeks later, as her 25-OHD level increased to near-normal levels. Her other symptoms also improved, and the only lesion left was a transient flat 3mm ulceration on her left thumb. A second female patient [age not stated] with a 25-OHD level of 4.9 ng/mL received fluorouracil, folinic acid [leucovorin] and oxaliplatin for pancreatic cancer [dosage details; time to reaction onset not stated]. Her dysgeusia improved after a week’s treatment with colecalciferol as her chemotherapy regimen was continued. Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. Journal of Clinical Oncology 29: e81-e82, No. 4, 1 Feb 2011. Available from: URL: http://dx.doi.org/10.1200/ jco.2010.31.5317 - Germany 803052087 » Editorial comment: A search of AdisBase, Medline and Embase did not reveal any previous case reports of stomatitis associated with trastuzumab or dysgeusia associated with carboplatin. The WHO-ADR database contained 29 reports of stomatitis and 18 reports of dysgeusia associated with trastuzumab and carboplatin, respectively. 1 Reactions 2 Apr 2011 No. 1345 0114-9954/10/1345-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
-
Upload
hoangtuyen -
Category
Documents
-
view
212 -
download
0
Transcript of Antineoplastics
Reactions 1345 - 2 Apr 2011
★Antineoplastics
Dermatitis, dysgeusia (first report for carboplatin)and stomatitis (first report for trastuzumab) inpatients with vitamin D deficiency: 2 case reports
Two women developed various toxicities, includingdysgeusia, following cancer chemotherapy.
In January 2010, a 59-year-old woman started receivingdocetaxel 75 mg/m2, carboplatin at AUC 6 and trastuzumab6 mg/kg on day 1 of each cycle [routes not stated]. Shedeveloped moderate dermatitis, moderate stomatitis andsignificant dysgeusia 1 week after receiving thesecond cycle. Two weeks after the third cycle, shepresented with a painful fissure on the flexor side of herright thumb, which was surrounded by flaky skin. A25 hydroxyvitamin D (25-OHD) level of 6.3 ng/mLconfirmed vitamin D deficiency. She received colecalciferol[vitamin D3] daily. At a follow-up 6 days later, her thumblesion had markedly improved and thefourth chemotherapy cycle was administered at the samedosage the next day. The lesions had almost totallyresolved about 2 weeks later, as her 25-OHD levelincreased to near-normal levels. Her other symptoms alsoimproved, and the only lesion left was a transient flat 3mmulceration on her left thumb.
A second female patient [age not stated] with a 25-OHDlevel of 4.9 ng/mL received fluorouracil, folinic acid[leucovorin] and oxaliplatin for pancreatic cancer [dosagedetails; time to reaction onset not stated]. Her dysgeusiaimproved after a week’s treatment with colecalciferol asher chemotherapy regimen was continued.Fink M. Vitamin D deficiency is a cofactor of chemotherapy-inducedmucocutaneous toxicity and dysgeusia. Journal of Clinical Oncology 29: e81-e82,No. 4, 1 Feb 2011. Available from: URL: http://dx.doi.org/10.1200/jco.2010.31.5317 - Germany 803052087
» Editorial comment: A search of AdisBase, Medline andEmbase did not reveal any previous case reports ofstomatitis associated with trastuzumab or dysgeusiaassociated with carboplatin. The WHO-ADR databasecontained 29 reports of stomatitis and 18 reports ofdysgeusia associated with trastuzumab and carboplatin,respectively.
1
Reactions 2 Apr 2011 No. 13450114-9954/10/1345-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
